Skip to main content
Policy & Funding· Daily Pulse

The Senate Just Told SAMHSA to Explain Its Own Harm Reduction Rules. Grantees Have Been Asking All Year.

The Senate's FY27 health bill keeps SAMHSA roughly flat, keeps NIDA and NIAAA separate, and slips in one sentence that matters more than the dollar figures.

ByThe Rize NewsroomNovember 21, 20262 min read

If you run a syringe program or a drop-in center on a SAMHSA grant, you have spent a good part of 2026 not knowing what you’re allowed to buy. SAMHSA’s April 24 letter cut off grant money for fentanyl and xylazine test strips handed to people who use drugs, and we covered who that landed on. On November 16 the Senate Appropriations Committee released its draft FY27 health spending bill, and buried in the committee’s report language is a sentence aimed straight at that confusion. The committee recognizes naloxone and other overdose-reversal work and directs SAMHSA to give grantees “timely and clarifying guidance” on eligible activities, according to a summary from the Association of State and Territorial Health Officials.

When Congress has to order an agency to tell its own grantees what is legal, the confusion was never an accident.

The money itself is mostly a hold-the-line story. The bill funds SAMHSA at $7.459 billion, about $20 million above this year, per the Addiction Policy Forum’s line-by-line table. State Opioid Response grants go to $1.61 billion, the substance use block grant to $2.023 billion, and the 988 crisis line to about $549.6 million. Sen. Shelley Moore Capito’s office lists $510.6 million for CDC overdose prevention and surveillance and $650.6 million for NIH’s HEAL Initiative, the pain-and-addiction research program.

Two things the Senate refused to do matter as much as what it funded. It did not adopt the White House plan to fold the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism into one new institute; NIDA gets $1.667 billion and NIAAA $595 million, separately. And, as the National Council of Urban Indian Health notes, it skipped the proposed new Administration for a Healthy America. For anyone whose recovery runs through alcohol research or SAMHSA-funded care, that’s the difference between an agency that knows your field and one rebuilt from scratch mid-crisis.

Now the honest caveat: none of this is law. NCUIH notes the bill isn’t expected to pass in its current form, and House and Senate negotiators still have to agree. The government runs on a continuing resolution that expires December 11, per the Congressional Research Service. A draft committee report is a signal, not a check in the mail.

If you are a grantee, here is the do-this-week move: put your eligibility questions about naloxone, test strips, and outreach supplies to your SAMHSA project officer in writing now, and keep the reply. When the “clarifying guidance” comes, you want a record of what you were told before it. And plan cash flow for a possible December 11 lapse or another stopgap.

Through all of it, naloxone stays recognized and fundable in the Senate’s own words. That is still yours. The question is whether the agency that hands it out will finally say, in plain English, what else is.

Filed Under

policyharm-reductionSAMHSANaloxoneHarm Reduction

Keep up with the reporting.

One email each morning with the stories that put days like this in context.

A daily, no-spam briefing. Unsubscribe anytime.

Continue reading

More from this section